HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A2580 Anti-C1q Anti-C1q (ANX005) is a recombinant antibody against C1q. It inhibits its function as the initiating molecule of the classical complement cascade. It is used in research of autoimmune and neurodegenerative diseases. MW:145.5 KD. Human IgG1
A2325 Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) is a monoclonal antibody targeting TNFRSF4. MW : 145.5 KD. Human IgG1
A2581 Icatolimab (Anti-BTLA / CD272) Icatolimab (Anti-BTLA / CD272) is a recombinant human monoclonal antibody which targets human BTLA protein. It neutralizes the interaction between BTLA and HVEM(Herpesvirus entry mediator). MW :145.5 KD. Human IgG4SP
A2326 Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) is a humanized monoclonal antibody against the OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for research on autoimmune diseases. MW : 145.5 KD. Human IgG1
A2582 Onvatilimab (Anti-B7-H5 / VISTA) Onvatilimab (Anti-B7-H5 / VISTA) is a human IgG1κ monoclonal antibody that targets and bind to VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). It has an anti-tumor activity. MW : 150 KD. Human IgG1
A2327 Ragifilimab (Anti-TNFRSF18 / GITR / CD357) Ragifilimab (Anti-TNFRSF18 / GITR / CD357) is an anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody with potential immune checkpoint modulating activity. MW : 145.5 KD. Human IgG1
A2583 Prezalumab (Anti-B7-H2 / ICOSL / CD275) Prezalumab (Anti-B7-H2 / ICOSL / CD275) is a human IgG2 monoclonal antibody targeting ICOSL and BAFF. It demonstrates studies for systemic lupus erythematosus arthritis. It is used in the research of Sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE).MW :145.5 KD. Human IgG2SA
A2329 Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD. Human IgG1
A2330 lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) Lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. MW : 145.5 KD. Human IgG1
A2331 Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) with a Kd of 1 nM and 0.8 nM for the long form and the short form of DR5, respectively. Conatumumab induces apoptosis via caspase activation. MW : 144.96 KD. Human IgG1
A3174 Mosunetuzumab (Anti-CD20 & CD3e) Mosunetuzumab is a bispecific T-cell-engaging monoclonal antibody that targets CD20 and CD3e, effectively redirecting T cells to eliminate CD20+ malignant B cells. It demonstrates promising efficacy in treating relapsed or refractory follicular lymphoma. MW: 146.72 KD. human IGg1
A2332 Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. MW : 145.5 KD. Human IgG2SA
A2588 Aducanumab (Anti-Amyloid Beta) Aducanumab (Anti-Amyloid Beta) is a selective human monoclonal antibody targeting aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.MW :145.5 KD. Human IgG1
A2333 Tomaralimab (Anti-TLR2 / CD282) Tomaralimab (Anti-TLR2 / CD282) is a humanized immunoglobulin (Ig) G4 monoclonal antibody directed against toll-like receptor type 2 (TLR2) with potential anti-inflammatory and antineoplastic activities. It has the potential for research on Myelodysplastic Syndromes (MDS). MW : 145.5 KD. Human IgG4SP
A2589 Birtamimab (Anti-Amyloid Alpha) Birtamimab(Anti-Amyloid Alpha) is an investigational monoclonal antibody that specifically and selectively targets and clear the amyloid. It can be used for treatment to remove amyloid from the vital organs, and research of light chain amyloidosis.MW :145.5 KD. Human IgG1
A2334 Tisotumab (Anti-Tissue factor / CD142) Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. MW : 145.5 KD. Human IgG1
A2590 Murlentamab (Anti-AMHR2) Murlentamab (Anti-AMHR2) is a humanized anti-AMHRII antibody targeting AMHRII. It suppresses tumor growth, stimulates the anti-tumor adaptive immune response through naive macrophage orientation and TAM reprogrammation, in ovarian tumor cells. MW :145.5 KD. Human IgG1
A2591 Cinpanemab (Anti-Alpha-synuclein) Cinpanemab(Anti-Alpha-synuclein) is a human-derived monoclonal antibody that targets and binds to α-synuclein. It can be used for the research of Parkinson's disease. MW : 146.98 KD. Human IgG1
A2336 Fresolimumab (Anti-TGFb1) Fresolimumab (Anti-TGFb1) is a pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) beta 1, 2, and 3 with potential antineoplastic activity. MW : 145.5 KD. Human IgG4SP
A2592 Praluzatamab (Anti-ALCAM / CD166) Praluzatamab (Anti-ALCAM / CD166) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). It can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates)which is used for research of cancers. MW : 150 KD. Human IgG1